Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study
Masatoshi Kudo, Zhenggang Ren, Yabing Guo, Guohong Han, Hailan Lin, Jinfang Zheng, Sadahisa Ogasawara, Ji Hoon Kim, Haitao Zhao, Chuan Li, David C. Madoff, R. Mark Ghobrial, Tomokazu Kawaoka, René Gérolami, Masafumi Ikeda, Hiromitsu Kumada, Anthony B. El-Khoueiry, Arndt Vogel, Xiang Peng, Kalgi Mody, Corina E. Dutcus, Leonid Dubrovsky, Abby B. Siegel, Richard S. Finn, Josep M. Llovet (2025). Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study. The Lancet, 405(10474), pp. 203-215, DOI: 10.1016/s0140-6736(24)02575-3.